11
Diffuse alveolar damage (DAD) was reported in 88% of patients with COVID-19. This is similar to both H1N1 (90%) and SARS (98%). Pulmonary microthrombi was reported in 57% of patients with COVID-19. This was similar to SARS... Read More
11 Tag: ARDS
11 8
In two early studies, researchers said some patients showed signs of healing just weeks after leaving the hospital. Lingering shortness of breath and diminished stamina have dogged many COVID patients whose lungs were viciously... Read More
9
The novel coronavirus 2019 (COVID-19) has caused a serious global pandemic in just eight months. Nearly every country and territory in the world has been affected by the virus. The virulence and infection rate of the virus... Read More
9
A number of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have been reported in neonates. Here, we aim to clarify the transmission route, clinical features and outcomes of these infections. We present... Read More
9
Elevated surfactant protein D levels are associated with severe acute respiratory distress syndrome and poor outcomes in children with acute respiratory failure, according to results published in Chest. Elevated surfactant... Read More
10
Acute Respiratory Distress Syndrome (ARDS) remains an important cause of morbidity and mortality worldwide, and the incidence is predicted to increase with the aging population. Several clinical disorders can initiate ARDS,... Read More
10
Older COVID-19 patients with higher APACHE II scores on admission, those who developed AKI grades II or III and/or septic shock during ICU stay had an increased risk-of-death. ICU mortality was 31%. A total of 663 patients... Read More
11
With great interest we read the article by Convertino et al. discussing potential treatment targets for pharmacological immunomodulation in coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS).... Read More
9
Now completely revised to bring you up to date with the latest advances in the field, Critical Care Medicine: Principles of Diagnosis and Management in the Adult, 5th Edition, delivers expert, practical guidance on virtually... Read More
8
Emerging data suggest a crucial role of endothelial dysfunction during SARS-CoV-2 infection, as a direct target of the virus and inflammatory cytokines as well as the main actor in orchestrating a pro-inflammatory and pro-coagulant... Read More
6
This study found a higher rate of gastrointestinal complications, including mesenteric ischemia, in critically ill patients with COVID-19 compared with propensity score–matched patients without COVID-19, suggesting a distinct... Read More
7
Fibrin-derived Peptide as Salvage Treatment in Critically Ill Patients with COVID-19-associated ARDS
After SARS-CoV-2 first occurred in China in December of 2019, it set out to become a global pandemic. Critically ill patients constitute about 2–9% of all infected patients and progress from pneumonia and hypoxemia to multi-organ... Read More
7
The COVID-19 pandemic has provided many intensivists (and some non-intensivists) several years’ worth of severe ARDS management experience over the course of just a few months. While the challenges have, in places,... Read More
8
Severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 frequently induces hypercoagulability with both microangiopathy and local thrombus formation, and a systemic coagulation defect that leads to large... Read More
9
In the midst of the 2009 influenza A H1N1 pandemic, clinicians turned to extracorporeal membrane oxygenation (ECMO) as a strategy to save lives. Based on the H1N1 experience, and the ECMO to Rescue Lung Injury in Severe Acute... Read More
![Between June 18 and Aug 3, 2020, Ministry of Health of the Russian Federation enrolled 76 participants to the two studies (38 in each study). In each study, 9 volunteers received rAd26-S in Phase 1, nine received rAd5-S in phase 1, and 20 received rAd26-S and rAd5-S in Phase 2. Both vaccine formulations were safe and well tolerated. In both Phase 1 and 2 studies of the Sputnik V vaccine all 76 participants developed antibodies to the virus that causes COVID-19. The most common adverse events were pain at injection site (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]), and muscle and joint pain (18 [24%]). Most adverse events were mild and no serious adverse events were detected. All participants produced antibodies to SARS-CoV-2 glycoprotein. Cell-mediated responses were detected in all participants at day 28, with median cell proliferation of 2·5% CD4+ and 1·3% CD8+ with the frozen formulation, and a median cell proliferation of 1·3% CD4+ and 1·1% CD8+ with the lyophilised formulation. The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.](https://criticalcare.news/wp-content/uploads/from-russia-with-love-sputnik-v-covid-19-vaccine-generated-an-immune-response-100x100.jpg)
